Precipio Announces Q2-2026 Financial Results
Precipio, Inc., a specialty cancer diagnostics company, announced strong financial results for Q2 2026, achieving record revenue of $7.0 million, a 22% year-over-year increase. The company also reported a positive adjusted EBITDA of $0.4 million and improved cash flow with a cash balance exceeding $3 million. The quarterly progress reflects growing…